The recent cancellation of a suspicious grant call in Slovakia has led to significant challenges for several leading biotechnology startups that had relied on these funds. Despite having signed contracts, many of these companies have not received any financial support, which has compelled them to scramble for alternative sources of funding to ensure the completion of their projects. This situation has particularly worried those involved in the global biotechnology field, known for their success at home and abroad.

The scandal arose from issues within the Slovak government, resulting in the resignation of Deputy Prime Minister Peter Kmec from the Hlas party. Initially, only three companies were stripped of their funding amid allegations of improper connections, but the fallout widened as 21 additional firms were subsequently affected. Some of these firms had already signed contracts, and while certain companies did obtain support, they faced new, unfavorable conditions, such as reduced grant amounts, altering their financial planning significantly.

Prominent Slovak scientist and CEO Pavol Čekan voiced his concerns, emphasizing that the abrupt reductions in grant amounts can mean substantial financial holes for these companies, with potential deficits exceeding a million euros. This kind of sudden financial shortfall poses severe challenges for innovative firms trying to remain competitive in a demanding field. The ramifications of this scandal highlight the fragility of the start-up ecosystem in Slovakia, especially in high-stakes sectors like biotechnology, where timely funding is crucial for survival and progress.